FDA user fee reauthorization meetings look to advance efforts associated with its Cell and Gene Therapy Program and Digital Health Program.
CDER Office of Prescription Drug Promotion director Tom Abrams retires after 27 years at FDA.
Medtronic agrees to pay $8.1 million to resolve allegations that it violated the False Claims Act by paying kickbacks to a physician.
Tricida says it is surprised that FDA does not believe its veverimer development program provides sufficient evidence for accelerated approval.
FDA continues a research agreement with Emulate to use its organ-chips in studies of Covid-19 vaccines.
Attorney Michael Kasser says requirements in a new FDA guidance could mean that medical device companies should avoid using nitinol unless its propert...
Panelists from FDA, universities, and private companies look at ways to better understand the heterogeneous treatment effects of drugs.
Federal Register notice: FDA announces an 11/19 virtual public meeting on reauthorizing the Biosimilar User Fee Act program.